AI-generated analysis. Always verify with the original filing.
Absci Corporation reported fourth quarter and full year 2025 financial results with Q4 revenue of $0.7 million and net loss of $29.6 million, and full year revenue of $2.8 million and net loss of $115.2 million. The company dosed first three cohorts in the ABS-201 Phase 1/2a HEADLINE trial, unveiled supporting ex vivo data, appointed Ransi Somaratne as Chief Medical Officer, and stated cash sufficient into first half of 2028.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 o
. Other Events. From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries
. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the Company on March 24, 2026, furnished herewith. 99.2 Absci Corporate Presentat
| Metric | Value | Basis |
|---|---|---|
| Revenue | $0.70 | GAAP |
| Revenue | $2.80 | GAAP |
| Research and development expenses | $25.30 | GAAP |
| Research and development expenses | $81.40 | GAAP |
| Selling, general, and administrative expenses | $8.60 | GAAP |
| Selling, general, and administrative expenses | $35.10 | GAAP |
| Net loss | $-29.60 | GAAP |
| Net loss | $-115.20 | GAAP |
| Net loss per share | $-0.20 | GAAP |
| Net loss per share | $-0.84 | GAAP |
Ransi Somaratne, M.D., FACC, MBA